MDT-AP-3082
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 122.03999999999999
- os_event
- false
- age_years
- 3.7
- sex
- F
- new_clusters
- S3
- umap1_2d
- -0.962870123
- umap2_2d
- -7.336132781
- umap1_3d
- -2.756779372
- umap2_3d
- -2.831118041
- umap3_3d
- 5.793497759
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- MYC_TARGETS_V1+0.470
- G2M_CHECKPOINT+0.450
- PANCREAS_BETA_CELLS+0.390
- SPERMATOGENESIS+0.280
- HEDGEHOG_SIGNALING+0.230
- APICAL_SURFACE+0.220
- CHOLESTEROL_HOMEOSTASIS+0.220
- MITOTIC_SPINDLE+0.170
- ANDROGEN_RESPONSE+0.150
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.470
- INTERFERON_GAMMA_RESPONSE-0.410
- TGF_BETA_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.270
- HEME_METABOLISM-0.270
- INFLAMMATORY_RESPONSE-0.240
- TNFA_SIGNALING_VIA_NFKB-0.240
- COAGULATION-0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 91648 | EPN | Supratentorial EPN | 0.850 |
| 2 | MNG1282 | — | — | 0.827 |
| 3 | BS_AM70R8RG | Med | Medulloblastoma | 0.822 |
| 4 | BS_V96WVE3Z | medulloblastoma | — | 0.814 |
| 5 | MNG592 | — | — | 0.807 |
| 6 | TCGA-63-A5MI-01A-12R-A27Q-07 | — | cohortSQ1 | 0.796 |
| 7 | SRR10900595 | — | — | 0.790 |
| 8 | BS_S69QZAJR | medulloblastoma | — | 0.787 |
| 9 | TCGA-85-8664-01A-11R-2403-07 | — | cohortMD1 | 0.786 |
| 10 | BS_AMZ70B6F | medulloblastoma | — | 0.786 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.390 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.220 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.150 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.020 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.020 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.010 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |